Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Cytokinetics Inc (CYTK)

444 + Investors. Track Smart Money conviction in CYTK. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +16
Streak
3Q ▲
Buyers last Q
56%

Smart Money Signals — CYTK

Based on 446 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 3 quarters in a row

last 6Q
For 3 consecutive quarters, more hedge funds added CYTK than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
446 hedge funds hold CYTK right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
🚀

Fast accumulation — +26% more funds vs a year ago

fund count last 6Q
+92 new funds entered over the past year (+26% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.
🟡

Slight buying edge — 56% buying

272 buying211 selling
Last quarter: 272 funds bought or added vs 211 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.
⚠️

Fewer new buyers each quarter (-21 vs last Q)

new funds entering per quarter
Funds opening this position for the first time: 29 → 102 → 102 → 81. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.
🔒

53% of holders stayed for 2+ years

■ 53% conviction (2yr+) ■ 21% medium ■ 25% new
238 out of 446 hedge funds have held CYTK for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
📈

Growing discovery — still being found

59 → 29 → 102 → 102 → 81 new funds/Q
New funds entering each quarter: 29 → 102 → 102 → 81. A growing number of institutions are discovering CYTK each quarter. The narrative is still spreading — leaving room for ongoing capital accumulation.
🏛️

Veteran-anchored — 62% veterans vs 26% newcomers

■ 62% veterans ■ 12% 1-2yr ■ 26% new
Entry-cohort mix of 488 holders: 302 (62%) are 2+ year veterans, 60 entered 1–2 years ago, and 126 (26%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
🏆

Elite ownership — 44% AUM from top-100 funds

44% from top-100 AUM funds
59 of 436 holders are among the 100 largest funds by AUM, controlling 44% of total institutional value in CYTK. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.
4.1
out of 10
Moderate Exit Risk
Exit risk score 4.1/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — CYTK

In 2026 Q1, 272 hedge funds were net buyers of CYTK (81 opened a new position, 191 added to an existing one), while 211 reduced or exited (146 trimmed, 65 sold completely) — a 56% buyer ratio, indicating a slight buying edge. This marks 3 consecutive quarters of net institutional buying — a persistent conviction signal. 44% of total institutional value in CYTK is held by top-100 AUM funds, reflecting elite-tier ownership quality. Net fund flow last quarter: +16 funds (more new holders than closures). Total institutional holders: 446.

Hedge Fund Ownership: CYTK

How many hedge funds hold CYTK — quarterly history vs. share price
Quarterly hedge fund ownership of CYTK vs. share price

Market Analysis: CYTK

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: CYTK

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Cytokinetics Inc (CYTK) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much CYTK has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 75d ago
CYTK
+6.4%
XLV
+4.9%

CYTK outperformed XLV by +1.5% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 30d ago
CYTK
-7.5%
XLV
+6.0%

Since the filing became public, CYTK outperformed XLV by -13.5% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

35 top-rated funds 16 high-conviction
Consensus
6.8
/ 10
breadth
×
Elite
4.8
/ 10
conviction
Hedge Fund Positioning: CYTK
444 + Investors

Track Smart Money conviction in CYTK. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 444 430 3.26%
13F Shares 156M 139M 12.21%
Total Value $8.92B $9.04B -1.33%
New Positions 81 102 -21
Increased Positions 183 149 +34
Closed Positions 67 55 +12
Reduced Positions 129 131 -2
Total Calls 32 25 28.0%
Total Puts 20 19 5.26%
PUT/CALL Ratio 0.62 0.76 Bullish

Statistics: CYTK

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

444 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in CYTK. Verified SEC 13F-HR filings.

QUARTER:
Top 25 CYTK holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Royalty Pharma Sub-Manager, LLC 36.36% 980,392 $62.3M
2 Foresite Capital Management IV, LLC 13.99% 503,295 $33.2M
3 Sarissa Capital Management LP 9.56% 228,623 $15.1M
4 Melqart Asset Management (UK) Ltd 5.48% 843,949 $55.6M
5 Integral Health Asset Management, LLC 5.04% 1,600,000 $105.5M
6 Trails Edge Capital Partners, LP 4.53% 300,000 $19.8M
7 Checkpoint Capital L.P. 4.26% 180,000 $11.9M
8 GSK plc 3.74% 340,434 $22.4M
9 Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. 3.69% 660,310 $43.5M
10 Monashee Investment Management LLC 3.59% 100,000 $6.6M
11 Exome Asset Management LLC 3.54% 103,718 $6.8M
12 Act Capital Management, LLC 3.34% 64,500 $4.3M
13 DAFNA Capital Management LLC 3.26% 217,497 $14.3M
14 Integral Health Asset Management, LLC 3.15% 1,000,000 $65.9M
15 Catalio Capital Management, LP 2.97% 215,501 $14.2M
16 Ikarian Capital, LLC 2.95% 550,500 $36.3M
17 Logos Global Management LP 2.88% 875,000 $57.7M
18 Sphera Funds Management LTD. 2.71% 259,300 $17.1M
19 MPM BioImpact LLC 2.54% 500,000 $33.0M
20 ADAR1 Capital Management, LLC 2.45% 632,556 $41.7M
21 Affinity Asset Advisors, LLC 2.38% 700,483 $46.2M
22 Diadema Partners LP 2.24% 200,000 $13.2M
23 Ikarian Capital, LLC 2.19% 408,400 $26.9M
24 Avoro Capital Advisors LLC 2.16% 3,333,333 $219.7M
25 First Turn Management, LLC 2.09% 283,700 $18.7M
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Cytokinetics Inc (CYTK)

What does the Smart Money Trend signal show for CYTK?

Buying streak — 3 quarters in a row: For 3 consecutive quarters, more hedge funds added CYTK than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for CYTK?

Slight buying edge — 56% buying: Last quarter: 272 funds bought or added vs 211 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for CYTK holders?

Elite ownership — 44% AUM from top-100 funds: 59 of 436 holders are among the 100 largest funds by AUM, controlling 44% of total institutional value in CYTK. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

How long have hedge funds held CYTK?

53% of holders stayed for 2+ years: 238 out of 446 hedge funds have held CYTK for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Cytokinetics Inc (CYTK) following the 2026 Q1 hedge fund 13F filings?

As of today, CYTK has moved -7.5% since the 2026 Q1 13F filing date (May 15, 2026), compared to +6.0% for the XLV sector ETF — an outperformance of -13.5%. Since the quarter end (March 31, 2026), CYTK has gained +6.4% vs +4.9% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →